Denali is providing updated guidance on cash operating expenses for FY24 and now anticipates an increase of approximately 5%-10% compared to 2023, which is an increase from previous guidance of equal to or less than FY23 cash operating expenses. This updated guidance is associated with increased activities to support filing of a BLA in early 2025 and commercial readiness for tividenofusp alfa in MPS II, and to accelerate the development of additional therapeutic programs in Denali’s TV platform portfolio.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNLI:
- Denali Therapeutics reports Q3 EPS (63c), consensus (61c)
- Denali Therapeutics price target raised to $45 from $40 at Jefferies
- DNLI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Denali Therapeutics’ Oditrasertib Phase 2 Study Discontinued
- Denali Therapeutics reinstated with a Market Perform at Raymond James
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
